CD28 and breast cancer: Immune checkpoints including PD-L1 (CD274), CD28 (CTLA-4 homolog), and CTLA-4, which are closely associated with BC immunotherapy, were enriched in the low-risk group (Figure 7(k)), indicating that these patients may be more sensitive to immunotherapy.